Boosts Muscle Mass CAS 863288-34-0 CJC-1295 Without DAC Growth Hormone Peptides

CJC 1295 without dac (synonym CJC 1295 w/o dac-complex, modified form GRF 1-29 without DAC-complex) belongs to peptides hormones and contains 29 amino acids; As well it is quite stable analog of growth hormone releasing hormone with D-Ala, Gln, Ala and Leu substitutions in certain positions - 2, 8, 18, 27, and in a such way it is enhance this protein's biological activity. Its molecular formula is C152H252N44O42 and its molecular mass is 3367.97.

In early 2000s few researches were done to determine if this representative of hormones can destroy visceral fat by promoting lipolysis. But actual development and synthetic production has started in year 2000 in Canada, while its mass production began in 2010-2011.

The biggest proven advantage of CJC 1295W/o dac is that it can biologically conjugate with albumin's serum which has impact on its effective half-life period and therapeutic range.

Moreover this synthetic drug of proteins' class can effectively stimulate the pituitary gland therefore making them to produce larger amount of hormone of growth. The main characteristic of this research compound is increasing peptides synthesis which causes rapid growth of muscles.

CJC-1295 is an injectable peptide used to increase GH production. This peptide is a growth hormone releasing hormone (GHRH) mimetic, or analog. That is to say, it works in the same way as GHRH, and may be referred to as being a GHRH.

The principal use of CJC-1295 is to provide increased GH levels, which also results in increased IGF-1 levels. An increase in these levels can aid fat loss and in some instances can aid muscle gain as well. Generally, a product in the GHRH category, including CJC-1295, is chosen as an alternate to using GH, and only rarely is combined with GH.

The other principal GHRH product is Mod GRF 1-29, which in most instances I recommend over CJC-1295. The products differ in their duration of action. Mod GRF has an approximately-ideal short duration of action allowing pulsatile dosing, whereas CJC-1295 has an extended duration of action which prevents such dosing.

DAC or no DAC?

As I have just stated above, when a person sees the term CJC 1295 without DAC this is really means that they are looking at MOD GRF 1-29. This tetrasubstitued peptide is a modified version of the original GRF 1-29 peptide better known as Semorelin. Due to the extreme short half life of the original GRF 1-29, chemists were able to modify the peptide to offer a longer biological activity that reduced the metabolic clearance. Although with MOD GRF 1-29 its modification had resulted in a greater peptide bond, the average user will still likely need to inject two to three times a day with a GHRP to get the maximum effectiveness for releasing endogenous growth hormone. Now when the drug affinity complex (DAC) was added to CJC 1295, it allowed for an even greater possibility to utilize smaller GH pulses (what was once thought of as a bleed) that, when combined with a GHRP, will activate growth hormone stores to release throughout the day and night. When the DAC component was added, this allowed the peptide half-life to be extended to about one week and also provided for steadier blood levels after injection. Now that we understand how important the DAC factor is, this becomes a much more viable and cost effective way to utilize CJC 1295 with DAC along with a GHRP. The DAC, when added, is able to bind to albumin that circulates the body, literally being able to last for days as it looks for receptors to bind to. So, in short, if you prefer to use shorter spikes of GH release then the use of the MOD GRF 1-29 (CJC 1295 without DAC) is going to be optimal. However, if your prefer fewer injections and still want to unleash your growth hormone stores, then 2-3 times a week injections of CJC 1295 with DAC along with your daily injection of GHRP would be the way to proceed for maximizing growth hormone release.

Applications:

CJC 1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.
At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 1000 mcg dose would require a volume of 1 mL, or “100 IU” as marked on an insulin syringe.

Injection may be subcutaneous, intramuscular, or intravenous according to personal preference. If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe, if there is room. This reduces the total number of injections required.

When recommending CJC 1295, I ordinarily recommend a dosage of 1000 mcg at a time, twice per week.

As with Mod GRF, CJC-1295 use can be combined with use of GHRP, but if using a GHRP, for superior results I recommend combining Mod GRF with it rather than CJC-1295.

The most important reason for this is observed results. The principal cause of it is that the DAC modification results in relatively lower levels of free peptide. In and of itself, this would be a bad thing, but it’s counterbalanced by the lower levels being sustained. However, if creating peaks with a GHRP, it’s more efficient to have higher levels of free GHRH peptide in, so to speak, “lock step” with those peaks. Mod GRF does this, while CJC-1925 does not.

If choosing CJC-1295 anyway to stack with a GHRP, dosing of the CJC-1295 remains as recommended above, while GHRP dosing will be typically 100 mcg at a time, or 50 mcg at a time if using hexarelin.